ArticleCancer communications (London, England)2025

Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01).

Chuanhua Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.